Vimarsana
Biggest News Aggregation in the World

Vector Evolution News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Vector Evolution. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Vector Evolution Today - Breaking & Trending Today

4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases - Vimarsana News

4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases

Published: January 3, 2024

Partnership brings together two leaders in next-generation genetic medicines to engineer, co-develop and co-commercialize AAV-delivered CRISPR/Cas-based therapeutics for up to six product candidates...

Source: marketscreener.com
Related Topics:
United KingdomUnited StatesJulian PeiDavid WaltDevyn SmithKatherine SmithDavid KirnFeng ZhangLou GehrigArbor Biotechnologies IncCorporate CommunicationsVerge Scientific CommunicationsExchange CommissionTherapeutic Vector EvolutionMolecular TherapeuticsArbor BiotechnologiesChief Executive OfficerNobel Prize WinningLooking StatementsPrivate Securities Litigation Reform ActCollaboration AgreementVector EvolutionMolecular TherapeuticAnnual ReportQuarterly Report
Astellas and 4D Molecular Therapeutics (4DMT) Enter into License Agreement to Use 4DMT's Proprietary Intravitreal R100 Vector for Rare Ophthalmic Targets - 4D Molecular Therapeutics (NASDAQ:FDMT), Astellas Pharma (OTC:ALPMY) - Vimarsana News

Astellas and 4D Molecular Therapeutics (4DMT) Enter into License Agreement to Use 4DMT's Proprietary Intravitreal R100 Vector for Rare Ophthalmic Targets - 4D Molecular Therapeutics (NASDAQ:FDMT), Astellas Pharma (OTC:ALPMY)

Published: July 11, 2023

TOKYO and EMERYVILLE, Calif., July 10, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President and CEO: Naoki Okamura, "Astellas") and 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) (CEO: David Kirn, MD,

Source: benzinga.com
Related Topics:
David KirnNaoki OkamuraAdam PearsonAstellas Pharma IncPrnewswire Astellas Pharma IncD Molecular Therapeutics IncExchange CommissionMolecular TherapeuticsChief Executive OfficerTherapeutic Vector EvolutionChief Strategy OfficerPrimary FocusesFocus Area ApproachNobel Prize WinningMolecular Therapeutic Forward Looking StatementsPrivate Securities Litigation Reform ActMolecular TherapeuticLicense AgreementMolecular Therapeutic Vector EvolutionVector EvolutionAnnual ReportQuarterly Report